Servando Palencia

748 total citations
15 papers, 599 citations indexed

About

Servando Palencia is a scholar working on Molecular Biology, Genetics and Genetics. According to data from OpenAlex, Servando Palencia has authored 15 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 3 papers in Genetics and 2 papers in Genetics. Recurrent topics in Servando Palencia's work include Fibroblast Growth Factor Research (10 papers), Epigenetics and DNA Methylation (3 papers) and Kruppel-like factors research (3 papers). Servando Palencia is often cited by papers focused on Fibroblast Growth Factor Research (10 papers), Epigenetics and DNA Methylation (3 papers) and Kruppel-like factors research (3 papers). Servando Palencia collaborates with scholars based in United States and United Kingdom. Servando Palencia's co-authors include Jingsong Zhao, Arie Abo, Walter D. Funk, Kyung‐Ah Kim, Marie-Claire Wagle, Kyuson Yun, Xiaoming Zhan, Jeong Kyo Yoon, Emily Park and Jackie Lee and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Servando Palencia

15 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Servando Palencia United States	9	377	86	85	77	72	15	599
Gregory J. Block United States	11	369 1.0×	99 1.2×	68 0.8×	67 0.9×	53 0.7×	13	742
Leonor Parreira Portugal	17	478 1.3×	66 0.8×	35 0.4×	101 1.3×	72 1.0×	101	1.2k
Christian N. Paxton United States	14	227 0.6×	127 1.5×	47 0.6×	74 1.0×	39 0.5×	33	631
Brisa Palikuqi United States	10	391 1.0×	126 1.5×	72 0.8×	41 0.5×	144 2.0×	12	721
Tapan Ganguly United States	12	289 0.8×	132 1.5×	32 0.4×	98 1.3×	57 0.8×	23	543
Brendan A.S. McIntyre Canada	18	335 0.9×	84 1.0×	192 2.3×	63 0.8×	86 1.2×	29	808
Smitha R. Georgy Australia	13	372 1.0×	116 1.3×	43 0.5×	83 1.1×	40 0.6×	21	566
Daniel Horbelt Germany	9	342 0.9×	64 0.7×	76 0.9×	102 1.3×	37 0.5×	10	593
Kenji Nagao Japan	15	478 1.3×	192 2.2×	105 1.2×	126 1.6×	157 2.2×	45	842
Federico A. Moretti Italy	10	200 0.5×	56 0.7×	127 1.5×	72 0.9×	178 2.5×	12	637

Countries citing papers authored by Servando Palencia

Since Specialization

Citations

This map shows the geographic impact of Servando Palencia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Servando Palencia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Servando Palencia more than expected).

Fields of papers citing papers by Servando Palencia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Servando Palencia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Servando Palencia. The network helps show where Servando Palencia may publish in the future.

Co-authorship network of co-authors of Servando Palencia

This figure shows the co-authorship network connecting the top 25 collaborators of Servando Palencia. A scholar is included among the top collaborators of Servando Palencia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Servando Palencia. Servando Palencia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Xiang, Hong, Ago Ahene, David I. Bellovin, et al.. (2021). Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. mAbs. 13(1). 1981202–1981202. 26 indexed citations

Powers, Janine, Servando Palencia, Susan P. Foy, et al.. (2016). Abstract 1407: FPA144, a therapeutic monoclonal antibody targeting the FGFR2b receptor, promotes antibody dependent cell-mediated cytotoxicity and stimulates sensitivity to PD-1 in the 4T1 syngeneic tumor model. Cancer Research. 76(14_Supplement). 1407–1407. 6 indexed citations

Bellovin, David I., Servando Palencia, Kevin Hestir, et al.. (2014). Abstract 5449: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC. Cancer Research. 74(19_Supplement). 5449–5449. 1 indexed citations

Gemo, Abigael T., Amit Deshpande, Servando Palencia, et al.. (2014). Abstract 5446: FPA144: A therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification. Cancer Research. 74(19_Supplement). 5446–5446. 13 indexed citations

Deshpande, Amit, Servando Palencia, David I. Bellovin, et al.. (2014). Abstract 2845: Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody. Cancer Research. 74(19_Supplement). 2845–2845. 4 indexed citations

Pierce, Kristen L., Amit Deshpande, Bradley A. Stohr, et al.. (2014). FPA144, a humanized monoclonal antibody for both FGFR2-amplified and nonamplified, FGFR2b-overexpressing gastric cancer patients.. Journal of Clinical Oncology. 32(15_suppl). e15074–e15074. 11 indexed citations

Harding, Thomas C., Li Long, Servando Palencia, et al.. (2013). Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer. Science Translational Medicine. 5(178). 178ra39–178ra39. 104 indexed citations

Harding, Thomas, Servando Palencia, Tiffany A. Wallace, et al.. (2012). Abstract 1876: Preclinical efficacy of fibroblast growth factor ligand trap HGS1036 in lung carcinoma models with genomic amplification of FGFR1. Cancer Research. 72(8_Supplement). 1876–1876. 1 indexed citations

Harding, Thomas C., Servando Palencia, Li Long, et al.. (2010). Abstract 2597: Preclinical efficacy of FP-1039 (FGFR1: Fc) in endometrial carcinoma models with activating mutations in FGFR2. Cancer Research. 70(8_Supplement). 2597–2597. 5 indexed citations

10.

Harding, Thomas C., et al.. (2010). Preclinical Effi cacy of FP-1039 (FGFR1:Fc) in Endometrial Carcinoma Models with Activating Mutations in FGFR2. 2 indexed citations

11.

Zhao, Jingsong, et al.. (2009). R-Spondin1 protects mice from chemotherapy or radiation-induced oral mucositis through the canonical Wnt/β-catenin pathway. Proceedings of the National Academy of Sciences. 106(7). 2331–2336. 96 indexed citations

12.

Zhao, Jingsong, et al.. (2008). rNAPc2 Inhibits Colorectal Cancer in Mice through Tissue Factor. Clinical Cancer Research. 15(1). 208–216. 42 indexed citations

13.

Park, Emily, Servando Palencia, Xiaoming Zhan, et al.. (2007). Mouse R-spondin2 is required for apical ectodermal ridge maintenance in the hindlimb. Developmental Biology. 311(1). 124–135. 100 indexed citations

14.

Zhao, Jingsong, Seiko Narushima, Eric X Beck, et al.. (2007). R-spondin1, A Novel Intestinotrophic Mitogen, Ameliorates Experimental Colitis in Mice. Gastroenterology. 132(4). 1331–1343. 105 indexed citations

15.

Tang, Yongkai, Tianhua Hu, Matthew Arterburn, et al.. (2005). The complete complement of C1q-domain-containing proteins in Homo sapiens. Genomics. 86(1). 100–111. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact